Conor E. Steuer, MD

One star
One star
One star
One star
One half star

Rating: 4.7 out of 5 (182 ratings)

Role

Medical Oncology
Specialty

Head and Neck Cancer Lung Cancer Thyroid Cancer Esophageal Cancer
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2015

Call 404-778-1900

Background

Conor E. Steuer, MD, is a board certified medical oncologist specializing in the care of aerodigestive cancers, mesothelioma and thymic malignancies. He joined the clinical staff at Winship Cancer Institute as a practicing physician in 2015.

Dr. Steuer is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He currently serves as chair of the Lung and Aerodigestive Malignancies Working Group.

Dr. Steuer received his medical degree from NYU School of Medicine. He completed his postdoctoral training as a Fellow in the Department of Hematology and Medical Oncology at Emory University School of Medicine where he was Chief Fellow in his final year.

Titles & Roles

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Education & Training

Education

Fellowship, Hematology & Oncology, 2015
Emory University School of Medicine
Residency, Internal Medicine, 2012
Emory University School of Medicine
Medical Education, MD, 2009
New York University

Board Certifications

Medical Oncology
American Board of Internal Medicine, 2015
Hematology
American Board of Internal Medicine, 2015
Internal Medicine
American Board of Internal Medicine, 2012

Research

Dr. Steuer has been active in research including clinical trial development, database analyses, and investigation of molecular biomarkers. He is interested in investigating the molecular biology and genomics of thoracic and head and neck tumors in order to be able to further the care of these patient populations. Additionally, he has taken an interest in utilizing national databases to perform clinical outcomes research, as well as further investigate rare forms of thoracic cancers.

View Current Clinical Trials


Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Phase II Conditions Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Location Emory University Hospital Midtown
Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers Phase II Conditions Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma Location Emory University Hospital Midtown
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer Phase II Conditions Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 Location Emory Saint Joseph's Hospital, Winship Cancer Institute
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer Phase II Conditions Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma Location Emory University Hospital Midtown, Winship Cancer Institute
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer Phase I Conditions Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8 Location Emory University Hospital Midtown, Winship Cancer Institute
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Phase I Conditions Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma Location Emory University Hospital Midtown, Winship Cancer Institute
VX15/2503 in Combination with Ipilimumab or Nivolumab in Patients with Head and Neck Cancer Phase I Conditions Squamous Cell Carcinoma of the Head and Neck Location Emory University Hospital Midtown, Winship Cancer Institute
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer Phase I Conditions Non-Small Cell Lung Cancer (NSCLC) Location Winship Cancer Institute

Publications

Dr. Steuer's work has been published in many leading journals, such as Cancer, Journal of Thoracic Oncology, and Lung Cancer, as well as presented at multiple international conferences.

Title/Journal	Authors	Publication Date
Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies. Cancers	E Xue, D Bracken-Clarke, H Krause, T Adeyelu, MG Evans, D Akbulut, M Quezado, N Gandhi, A Farrell, HP Soares, E Lou, M Phan, R Patel, AM Vanderwalde, A Elliott, CE Steuer, NF Saba, DJ Lubin, NR London, JL Gulley, CS Floudas	11/24/2024
Institution-level Patterns of Care for Early-stage Oropharynx Cancers in the United States. American journal of clinical oncology	JR Janopaul-Naylor, Y Liu, Y Cao, AJ Schlafstein, C Steuer, MR Patel, JE Bates, MW McDonald, WA Stokes	11/01/2024
Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research	NF Saba, R Chaudhary, K Kirtane, A Marra, A Ekpenyong, A McCook-Veal, NC Schmitt, JH Gross, MR Patel, J Remick, JE Bates, MW McDonald, SF Rudra, WA Stokes, M Biernacki, X Song, RJC Slebos, Y Liu, CE Steuer, DM Shin, Y Teng, CH Chung	10/15/2024
Assessing survival outcomes of patients with oral tongue squamous cell carcinoma: Focus on age, sex, and stage. Head & neck	S Pamulapati, M Abousaud, Y Li, A Ekpenyong, S Rudra, JS Remick, JE Bates, WA Stokes, MW McDonald, NC Schmitt, MW El-Deiry, MR Patel, CE Steuer, JM Switchenko, DM Shin, Y Teng, A Hammond, NF Saba	09/01/2024
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial. JAMA oncology	NF Saba, SJ Wong, T Nasti, AA McCook-Veal, MW McDonald, WA Stokes, AM Anderson, A Ekpenyong, M Rupji, M Abousaud, S Rudra, JE Bates, JS Remick, NP Joshi, NM Woody, M Awan, JL Geiger, A Shreenivas, J Samsa, MC Ward, NC Schmitt, MR Patel, KA Higgins, Y Teng, CE Steuer, DM Shin, Y Liu, R Ahmed, SA Koyfman	07/01/2024
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations. The Lancet. Oncology	AM Lim, C Le Tourneau, C Hurt, SG Laskar, CE Steuer, VLY Chow, P Szturz, C Henson, AT Day, JE Bates, S Lazarakis, L McDowell, H Mehanna, SS Yom	07/01/2024
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI. Future oncology (London, England)	T Mok, PA Jänne, M Nishio, S Novello, M Reck, C Steuer, YL Wu, R Fougeray, PD Fan, J Meng, DW Sternberg, S Esker, HA Yu	05/01/2024
Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement. The Laryngoscope	RJ So, JC Hidalgo Lopez, SA Ballestas, AM Klein, C Steuer, DM Shin, M Abousaud, Y Teng, NF Saba, AT Tkaczuk, ES Schaefer, TY Seiwert, K McClellan, SR Best	02/01/2024
Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer. Cancer	NS McCall, JR Janopaul-Naylor, HS McGinnis, AH Kesarwala, S Tian, WA Stokes, JW Shelton, CE Steuer, JW Carlisle, TA Leal, SS Ramalingam, JD Bradley, KA Higgins	12/01/2023
Long-Term Follow-up of Parenteral Bevacizumab In Patients with Recurrent Respiratory Papillomatosis. The Laryngoscope	SA Ballestas, J Hidalgo Lopez, AM Klein, C Steuer, DM Shin, M Abousaud, NC Schmitt, Y Teng, NF Saba, AT Tkaczuk	10/01/2023
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	JE Bauman, NF Saba, D Roe, JR Bauman, J Kaczmar, A Bhatia, J Muzaffar, R Julian, S Wang, S Bearelly, A Baker, C Steuer, A Giri, B Burtness, S Centuori, C Caulin, R Klein, K Saboda, S Obara, CH Chung	08/01/2023
Patient-reported outcomes in immunotherapy for head and neck cancer. Head & neck	K Kirtane, AI Hoogland, X Li, Y Rodriguez, K Scheel, BJ Small, LB Oswald, J Muzaffar, JA Kish, M Bonomi, P Bhateja, NF Saba, CE Steuer, CH Chung, HSL Jim	07/01/2023
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research	DS Hong, M Postow, B Chmielowski, R Sullivan, A Patnaik, EEW Cohen, G Shapiro, C Steuer, M Gutierrez, H Yeckes-Rodin, R Ilaria, B O'Connell, J Peng, G Peng, N Zizlsperger, A Tolcher, JD Wolchok	06/13/2023
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. Nature medicine	NF Saba, CE Steuer, A Ekpenyong, A McCook-Veal, K Magliocca, M Patel, NC Schmitt, W Stokes, JE Bates, S Rudra, J Remick, M McDonald, M Abousaud, AC Tan, MZH Fadlullah, R Chaudhary, J Muzaffar, K Kirtane, Y Liu, GZ Chen, DM Shin, Y Teng, CH Chung	04/01/2023
Ninety-day mortality following transoral robotic surgery or radiation at Commission on Cancer-accredited facilities. Head & neck	JR Janopaul-Naylor, M Rupji, RA Tobillo, JW Lorenz, JM Switchenko, S Tian, AS Kaka, DC Qian, AJ Schlafstein, CE Steuer, JS Remick, S Rudra, MW McDonald, NF Saba, WA Stokes, MR Patel, JE Bates	03/01/2023
The evolving landscape of salivary gland tumors. CA: a cancer journal for clinicians	CE Steuer, GJ Hanna, K Viswanathan, JE Bates, AS Kaka, NC Schmitt, AL Ho, NF Saba	01/01/2023
Critical review of the current and future prospects of VEGF-TKIs in the management of squamous cell carcinoma of head and neck. Frontiers in oncology	P Puttagunta, SV Pamulapati, JE Bates, JH Gross, WA Stokes, NC Schmitt, C Steuer, Y Teng, NF Saba	01/01/2023
Specimen-Based Resection Margins and Local Control during Transoral Robotic Surgery for Oropharyngeal HPV-Mediated Squamous Cell Carcinoma. ORL; journal for oto-rhino-laryngology and its related specialties	KR Magliocca, AS Kaka, EM Barrow, MB Studer, CC Griffith, J Ernst, T Meade, A Balicki, BJ Boyce, NC Schmitt, AM Bur, AC Schmitt, R Jackson, CE Steuer, JJ Beitler, MR Patel	01/01/2023
Immune check point inhibitors in advanced cutaneous squamous cell carcinomas: "Repeat and replicate". Cancer	CE Steuer, NF Saba	12/15/2022
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	RM Valanparambil, J Carlisle, SL Linderman, A Akthar, RL Millett, L Lai, A Chang, AA McCook-Veal, J Switchenko, TH Nasti, M Saini, A Wieland, KE Manning, M Ellis, KM Moore, SL Foster, K Floyd, ME Davis-Gardner, VV Edara, M Patel, C Steur, AK Nooka, F Green, MA Johns, F O'Brein, U Shanmugasundaram, VI Zarnitsyna, H Ahmed, LE Nyhoff, G Mantus, M Garett, S Edupuganti, M Behra, R Antia, J Wrammert, MS Suthar, MV Dhodapkar, S Ramalingam, R Ahmed	11/20/2022
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade. Clinical lung cancer	BE Osta, J Carlisle, C Steuer, S Pakkala, T Leal, M Dhodapkar, Y Liu, Z Chen, T Owonikoko, S Ramalingam	11/01/2022
Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology	NS McCall, HS McGinnis, JR Janopaul-Naylor, AH Kesarwala, S Tian, WA Stokes, JW Shelton, CE Steuer, JW Carlisle, T Leal, SS Ramalingam, JD Bradley, KA Higgins	09/01/2022
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research	CH Chung, J Li, CE Steuer, P Bhateja, M Johnson, J Masannat, MI Poole, F Song, JC Hernandez-Prera, H Molina, BM Wenig, S Kumar, C Kuperwasser, PJ Stephens, JM Farinhas, DM Shin, JA Kish, J Muzaffar, K Kirtane, JW Rocco, MJ Schell, NF Saba, M Bonomi	06/01/2022
T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. Journal for immunotherapy of cancer	X Wang, J Muzaffar, K Kirtane, F Song, M Johnson, MJ Schell, J Li, SJ Yoder, JR Conejo-Garcia, JA Guevara-Patino, M Bonomi, P Bhateja, JW Rocco, CE Steuer, NF Saba, CH Chung	06/01/2022
A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer. Cancers	JE Bauman, Z Chen, C Zhang, JP Ohr, RL Ferris, GM McGorisk, S Brandt, S Srivatsa, AY Chen, CE Steuer, DM Shin, NF Saba, FR Khuri, TK Owonikoko	05/26/2022
Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab. Oral oncology	DJ Glazar, M Johnson, J Farinhas, CE Steuer, NF Saba, M Bonomi, CH Chung, H Enderling	04/01/2022
HPV as a Carcinomic Driver in Head and Neck Cancer: a De-escalated Future? Current treatment options in oncology	JE Bates, CE Steuer	03/01/2022
Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell Carcinomas. The oncologist	P Vijayvargiya, S Trivedi, M Rupji, H Song, Y Liu, R Jiang, AS Kaka, GZ Chen, W Stokes, C Steuer, DM Shin, JJ Beitler, MR Patel, A Aiken, NF Saba	02/03/2022
The omission of intentional primary site radiation following transoral robotic surgery in 59 patients: No local-regional failures. Head & neck	VR Dhere, CE Escott, S Tian, JM Switchenko, JP Bell, WA Stokes, MW McDonald, KR Magliocca, BJ Boyce, AS Kaka, CE Steuer, NF Saba, DM Shin, C Xiao, MR Patel, JJ Beitler	02/01/2022
Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern. medRxiv : the preprint server for health sciences	R Valanparambil, J Carlisle, S Linderman, A Akthar, RL Millett, L Lai, A Chang, A McCook, J Switchenko, T Nasti, M Saini, AW Andreas Wieland, K Manning, M Ellis, K Moore, S Foster, K Floyd, M Davis-Gardner, V Viswanadh Edara, M Patel, C Steur, A Nooka, F Green, M Johns, F O Brein, U Shanmugasundaram, V Zarnitsyna, H Ahmed, L Nyhoff, G Mantus, M Garett, S Edupuganti, M Behra, R Antia, J Wrammert, M Suthar, M Dhodapkar, S Ramalingam, R Ahmed	01/23/2022
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer discovery	PA Jänne, C Baik, WC Su, ML Johnson, H Hayashi, M Nishio, DW Kim, M Koczywas, KA Gold, CE Steuer, H Murakami, JC Yang, SW Kim, M Vigliotti, R Shi, Z Qi, Y Qiu, L Zhao, D Sternberg, C Yu, HA Yu	01/01/2022
Advances in Immunotherapy and Implications for Current Practice in Non-Small-Cell Lung Cancer. JCO oncology practice	CE Steuer, SS Ramalingam	11/01/2021
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors. The oncologist	KT Do, LQM Chow, K Reckamp, RE Sanborn, H Burris, F Robert, DR Camidge, CE Steuer, JH Strickler, A Weise, JM Specht, M Gutierrez, P Haughney, S Hengel, CL Derleth, TA Yap	11/01/2021
Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population--A SEER-based analysis from 2000 to 2016. Cancer medicine	MA Taylor, J Switchenko, W Stokes, MR Patel, M McDonald, C Steuer, A Aiken, JJ Beitler, DM Shin, NF Saba	09/01/2021
Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology	F Carsuzaa, M Lapeyre, V Gregoire, P Maingon, A Beddok, PY Marcy, J Salleron, A Coutte, S Racadot, Y Pointreau, P Graff, B Beadle, K Benezery, J Biau, V Calugaru, J Castelli, M Chua, A Di Rito, M Dore, P Ghadjar, F Huguet, P Jardel, J Johansen, R Kimple, M Krengli, S Laskar, L Mcdowell, A Nichols, S Tribius, I Valduvieco, C Hu, X Liem, A Moya-Plana, I D'onofrio, U Parvathaneni, V Takiar, E Orlandi, A Psyrri, G Shenouda, D Sher, C Steuer, X Shan Sun, Y Tao, D Thomson, MH Tsai, N Vulquin, P Gorphe, H Mehanna, SS Yom, J Bourhis, J Thariat	07/01/2021
Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	CE Steuer, OA Jegede, SE Dahlberg, HA Wakelee, SM Keller, WJ Tester, DR Gandara, SL Graziano, AA Adjei, CA Butts, SS Ramalingam, JH Schiller	06/01/2021
TORS elective lingual tonsillectomy has less acute morbidity than therapeutic base of tongue TORS. Oral oncology	MR Patel, L Ottenstein, M Ryan, A Farrell, M Studer, HM Baddour, K Magliocca, C Griffith, W Stokes, J Switchenko, A Aiken, M El-Deiry, CA Solares, C Steuer, N Saba, J Beitler	06/01/2021
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. Cancers	CH Chung, M Bonomi, CE Steuer, J Li, P Bhateja, M Johnson, J Masannat, F Song, JC Hernandez-Prera, BM Wenig, H Molina, JM Farinhas, CP McMullen, JT Wadsworth, KB Patel, JA Kish, J Muzaffar, K Kirtane, JW Rocco, MJ Schell, NF Saba	03/09/2021
Socioeconomic Factors Influence the Impact of Tumor HPV Status on Outcome of Patients With Oropharyngeal Squamous Cell Carcinoma. JCO oncology practice	JA Marks, JM Switchenko, CE Steuer, M Ryan, MR Patel, MW McDonald, K Higgins, JJ Beitler, DM Shin, TW Gillespie, NF Saba	03/01/2021
Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population. The Laryngoscope	A Tkaczuk, S Trivedi, MD Mody, CE Steuer, DM Shin, AM Klein, NF Saba	03/01/2021
Surgical Resection is Justifiable for Oral T4b Squamous Cell Cancers With Masticator Space Invasion. The Laryngoscope	HM Baddour, MC Ochsner, MR Patel, JM Switchenko, JJ Beitler, K Magliocca, KL Baugnon, CA Solares, CE Steuer, MW El-Deiry	02/01/2021
Combinatorial approaches targeting the EGFR family and c-Met in SCCHN. Oral oncology	D Wang, Y Lu, S Nannapaneni, CC Griffith, C Steuer, G Qian, X Wang, Z Chen, M Patel, M El-Deiry, DM Shin, X He, ZG Chen, NF Saba	01/01/2021
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. Journal for immunotherapy of cancer	S Pakkala, K Higgins, Z Chen, G Sica, C Steuer, C Zhang, G Zhang, S Wang, MS Hossain, B Nazha, T Beardslee, FR Khuri, W Curran, S Lonial, EK Waller, S Ramalingam, TK Owonikoko	12/01/2020
Outcomes and Predictive Value of Post-adjuvant Therapy PET/CT for Locally Advanced Oral Squamous Cell Carcinoma. The Laryngoscope	DC Qian, KR Magliocca, AH Aiken, KL Baugnon, DC Brandon, WA Stokes, MW McDonald, MR Patel, HM Baddour, AS Kaka, CE Steuer, NF Saba, DM Shin, JJ Beitler	12/01/2020
Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. Clinical cancer research : an official journal of the American Association for Cancer Research	DM Shin, S Nannapaneni, MR Patel, Q Shi, Y Liu, Z Chen, AY Chen, MW El-Deiry, JJ Beitler, CE Steuer, SM Roser, AM Klein, TK Owonikoko, SS Ramalingam, FR Khuri, ZG Chen, NF Saba	11/15/2020
An update on the immune landscape in lung and head and neck cancers. CA: a cancer journal for clinicians	JW Carlisle, CE Steuer, TK Owonikoko, NF Saba	11/01/2020
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. British journal of cancer	RD Harvey, BC Carthon, C Lewis, MS Hossain, C Zhang, Z Chen, WB Harris, OB Alese, W Shaib, MA Bilen, DH Lawson, C Wu, CE Steuer, BF El-Rayes, FR Khuri, S Lonial, EK Waller, SS Ramalingam, TK Owonikoko	10/01/2020
EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic? Translational lung cancer research	CE Steuer, SS Ramalingam	10/01/2020
Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. International journal of radiation oncology, biology, physics	S Tian, JM Switchenko, ZS Buchwald, PR Patel, JW Shelton, SE Kahn, RN Pillai, CE Steuer, TK Owonikoko, M Behera, WJ Curran, KA Higgins	09/01/2020
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research	TK Owonikoko, RD Harvey, B Carthon, Z Chen, C Lewis, H Collins, C Zhang, DH Lawson, OB Alese, MA Bilen, GL Sica, CE Steuer, WL Shaib, C Wu, WB Harris, M Akce, RR Kudchagkar, BF El-Rayes, S Lonial, SS Ramalingam, FR Khuri	06/01/2020
Demographic and Socioeconomic Factors Associated With Metastases at Presentation in HPV-Related Squamous Cell Carcinoma of the Head and Neck: An NCDB Analysis. JCO oncology practice	MB Bean, JM Switchenko, CE Steuer, M Patel, K Higgins, M McDonald, GZ Chen, JJ Beitler, DM Shin, T Gillespie, NF Saba	06/01/2020
Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis. The oncologist	M Behera, CE Steuer, Y Liu, F Fernandez, C Fu, KA Higgins, TW Gillespie, S Pakkala, RN Pillai, S Force, CP Belani, FR Khuri, WJ Curran, SS Ramalingam	06/01/2020
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. The oncologist	MA Bilen, DJ Martini, Y Liu, JM Shabto, JT Brown, M Williams, AI Khan, A Speak, C Lewis, H Collins, HT Kissick, BC Carthon, M Akce, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master	03/01/2020
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer	DJ Martini, MR Kline, Y Liu, JM Shabto, MA Williams, AI Khan, C Lewis, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master, MA Bilen	02/01/2020
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. The Lancet. Oncology	RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, CM Blakely, T Seto, BC Cho, D Tosi, B Besse, SP Chawla, L Bazhenova, JC Krauss, YK Chae, M Barve, I Garrido-Laguna, SV Liu, P Conkling, T John, M Fakih, D Sigal, HH Loong, GL Buchschacher, P Garrido, J Nieva, C Steuer, TR Overbeck, DW Bowles, E Fox, T Riehl, E Chow-Maneval, B Simmons, N Cui, A Johnson, S Eng, TR Wilson, GD Demetri	02/01/2020
Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC). PloS one	NF Saba, AR Dinasarapu, KR Magliocca, B Dwivedi, S Seby, ZS Qin, M Patel, CC Griffith, X Wang, M El-Deiry, CE Steuer, J Kowalski, DM Shin, ME Zwick, ZG Chen	01/01/2020
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Investigational new drugs	DJ Martini, Y Liu, JM Shabto, C Lewis, MR Kline, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, VA Master, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, MA Bilen	12/01/2019
Small Cell and Squamous Cell Carcinomas of the Head and Neck: Comparing Incidence and Survival Trends Based on Surveillance, Epidemiology, and End Results (SEER) Data. The oncologist	MB Bean, Y Liu, R Jiang, CE Steuer, M Patel, MW McDonald, KA Higgins, JJ Beitler, DM Shin, NF Saba	12/01/2019
Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database. Clinical lung cancer	S Tian, X Zhang, R Jiang, RN Pillai, TK Owonikoko, CE Steuer, NF Saba, S Pakkala, PR Patel, CP Belani, FR Khuri, WJ Curran, SS Ramalingam, M Behera, KA Higgins	11/01/2019
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. The Lancet. Oncology	D Adkins, J Ley, P Neupane, F Worden, AG Sacco, K Palka, JE Grilley-Olson, R Maggiore, NN Salama, K Trinkaus, BA Van Tine, CE Steuer, NF Saba, P Oppelt	09/01/2019
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC cancer	MA Bilen, JM Shabto, DJ Martini, Y Liu, C Lewis, H Collins, M Akce, H Kissick, BC Carthon, WL Shaib, OB Alese, CE Steuer, C Wu, DH Lawson, R Kudchadkar, VA Master, B El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey	08/29/2019
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung cancer (Amsterdam, Netherlands)	MM Awad, GC Leonardi, S Kravets, SE Dahlberg, A Drilon, SA Noonan, DR Camidge, SI Ou, DB Costa, SM Gadgeel, CE Steuer, PM Forde, VW Zhu, Y Fukuda, JW Clark, PA Jänne, T Mok, LM Sholl, RS Heist	07/01/2019
Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. Head & neck	A Mohamed, B Twardy, MA Zordok, K Ashraf, A Alkhoder, K Schrapp, C Steuer, Z Chen, S Pakkala, R Pillai, J Trad Wadsworth, K Higgins, JJ Beitler, SS Ramalingam, TK Owonikoko, FR Khuri, DM Shin, M Behera, NF Saba	05/01/2019
Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx. Cancer	JJ Beitler, JM Switchenko, JJ Dignam, MW McDonald, NF Saba, DM Shin, KR Magliocca, RJ Cassidy, MW El-Deiry, MR Patel, CE Steuer, C Xiao, PA Hudgins, AH Aiken, WJ Curran, QT Le	03/01/2019
Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas. The Laryngoscope	RJ Cassidy, JM Switchenko, MW El-Deiry, RH Belcher, J Zhong, CE Steuer, NF Saba, MW McDonald, DS Yu, TW Gillespie, JJ Beitler	02/01/2019
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer	MA Bilen, DJ Martini, Y Liu, C Lewis, HH Collins, JM Shabto, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, VA Master, SS Ramalingam, TK Owonikoko, RD Harvey	01/01/2019
Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. Cancer	RH Press, C Zhang, RJ Cassidy, MJ Ferris, J Zhong, CE Steuer, RN Pillai, TK Owonikoko, S Kahn, SS Ramalingam, PR Patel, WJ Curran, HG Shu, GL Sica, KA Higgins	09/01/2018
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer cell	L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi, X Wang, HB Kang, L Song, D Wang, G Zhang, J Fan, TJ Boggon, L Zhou, J Kowalski, CK Qu, CE Steuer, GZ Chen, NF Saba, LH Boise, TK Owonikoko, FR Khuri, KR Magliocca, DM Shin, S Lonial, S Kang	08/13/2018
Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine? Journal of clinical oncology : official journal of the American Society of Clinical Oncology	CE Steuer, SS Ramalingam	03/01/2018
A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. Molecular cancer therapeutics	CE Steuer, CC Griffith, S Nannapaneni, MR Patel, Y Liu, KR Magliocca, MW El-Deiry, C Cohen, TK Owonikoko, DM Shin, ZG Chen, NF Saba	03/01/2018
Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer	RJ Cassidy, X Zhang, JM Switchenko, PR Patel, JW Shelton, S Tian, RH Nanda, CE Steuer, RN Pillai, TK Owonikoko, SS Ramalingam, FG Fernandez, SD Force, TW Gillespie, WJ Curran, KA Higgins	02/15/2018
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Annals of oncology : official journal of the European Society for Medical Oncology	J Remon, CE Steuer, SS Ramalingam, E Felip	01/01/2018
Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology	MJ Ferris, J Zhong, JM Switchenko, KA Higgins, RJ Cassidy, MW McDonald, BR Eaton, KR Patel, CE Steuer, HM Baddour, AH Miller, DW Bruner, C Xiao, JJ Beitler	01/01/2018
Health care disparities among octogenarians and nonagenarians with stage II and III rectal cancer. Cancer	RJ Cassidy, JM Switchenko, E Cheng, R Jiang, J Jhaveri, KR Patel, DG Tanenbaum, MC Russell, CE Steuer, TW Gillespie, MW McDonald, JC Landry	11/15/2017
Guideline-concordant Care Improves Overall Survival for Locally Advanced Non-Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis. Clinical lung cancer	HZ Ahmed, Y Liu, K O'Connell, MZ Ahmed, RJ Cassidy, TW Gillespie, P Patel, RN Pillai, M Behera, CE Steuer, TK Owonikoko, SS Ramalingam, WJ Curran, KA Higgins	11/01/2017
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer. Journal of the National Cancer Institute	DA Goldstein, N Gordon, M Davidescu, M Leshno, CE Steuer, N Patel, SM Stemmer, A Zer	11/01/2017
Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	KA Higgins, RN Pillai, Z Chen, S Tian, C Zhang, P Patel, S Pakkala, J Shelton, SD Force, FG Fernandez, CE Steuer, TK Owonikoko, SS Ramalingam, JD Bradley, WJ Curran	11/01/2017
Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy. Cancer	RJ Cassidy, X Zhang, PR Patel, JW Shelton, CE Escott, GL Sica, MR Rossi, CE Hill, CE Steuer, RN Pillai, SS Ramalingam, TK Owonikoko, M Behera, SD Force, FG Fernandez, WJ Curran, KA Higgins	10/01/2017
Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. Cancer	KB Naik, Y Liu, M Goodman, TW Gillespie, A Pickens, SD Force, CE Steuer, TK Owonikoko, SS Ramalingam, K Higgins, JJ Beitler, DM Shin, FF Willingham, B El-Rayes, JC Landry, FG Fernandez, NF Saba	09/15/2017
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review. JAMA oncology	CE Steuer, M Behera, V Ernani, KA Higgins, NF Saba, DM Shin, S Pakkala, RN Pillai, TK Owonikoko, WJ Curran, CP Belani, FR Khuri, SS Ramalingam	08/01/2017
Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. Clinical lung cancer	CE Steuer, M Behera, Y Liu, C Fu, TW Gillespie, NF Saba, DM Shin, RN Pillai, S Pakkala, TK Owonikoko, FR Khuri, SS Ramalingam	05/01/2017
Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base. Cancer	RJ Cassidy, Y Liu, K Patel, J Zhong, CE Steuer, DA Kooby, MC Russell, TW Gillespie, JC Landry	03/01/2017
The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer. Annual review of medicine	V Ernani, CE Steuer, M Jahanzeb	01/14/2017
An update on larynx cancer. CA: a cancer journal for clinicians	CE Steuer, M El-Deiry, JR Parks, KA Higgins, NF Saba	01/01/2017
Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. Oncology	M Evans, Y Liu, C Chen, C Steuer, R Cassidy, J Landry, K Higgins, JJ Beitler, F Willingham, TK Owonikoko, SS Ramalingam, DM Shin, NK Jegadeesh, B El-Rayes, F Fernandez, AM Krasinskas, T Gillespie, NF Saba	01/01/2017
Development of Late Toxicities in Patients with Oral Tongue Cancer Treated with Surgical Resection and Adjuvant Radiation Therapy. Frontiers in oncology	M Sayan, RJ Cassidy, JM Switchenko, OA Kayode, NF Saba, CE Steuer, DM Shin, JT Wadsworth, M El-Deiry, M Patel, JJ Beitler, KA Higgins	01/01/2016

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.7	One star One star One star One star One half star	Provider showed concern
4.7	One star One star One star One star One half star	Provider explained things clearly
4.7	One star One star One star One star One half star	Provider discussed treatment options
4.7	One star One star One star One star One half star	Provider included you in decisions
4.7	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	01/19/2025	Dr. Steuer is the best!
One star One star One star One star One star	01/17/2025	First appointment with this doctor. Felt very at ease and he showed interest ion my questions, etc. I was so very pleased.
One star One star One star One star One star	01/11/2025	Dr Steuer is very professional and knowledgeable. He is great Dr to take care of patients
One star One star One star One star One star	12/06/2024	Very Good
One star One star One star One star One star	11/06/2024	Listened carefullly and provided guidance on what the next step should be.
One star One star One star One star One star	10/27/2024	Feel like Dr Steuer is genuinely interested and open to all possible protocols to beat cancer. He is very accessible and shows true care for my quality of life.
One star One star One star One star One star	10/26/2024	Dr. Steuer Is absolutely the best and his staff are outstanding!
One star One star One star One star One star	10/16/2024	Everybody that talked to me.Seemed to be on the same page and knew what the situation was.I'm very pleased
One star One star One star One star One star	09/18/2024	Excellent
One star One star One star One star One star	07/23/2024	Dr Steuer provided the options I have, fully explaining them. Answered all questions asked and addressed our concerns.
One star One star One star One star One star	07/22/2024	Always tell people to use my Dr
One star One star One star One star One star	03/09/2024	Dr. Stuer has been amazing and I truly appreciate him.
One star One star One star One star One star	01/14/2024	Dr. Stuer has been amazing and we are very grateful for his help.
One star One star One star One star One star	01/11/2024	Dr. Steurer was very helpful
One star One star One star One star Empty star	10/21/2023	It was a lot of information. Some handouts or a summary would be helpful.
One star One star One star One star One star	10/17/2023	Good
One star One star One star One star One star	10/03/2023	Love Dr Steuer
One star One star One star One star One star	09/08/2023	Very professional & caring Answers all our questions, listens to our concerns Never feel rushed.
One star One star One star One star One half star	08/25/2023	Great
One star One star One star One star One star	07/06/2023	Very thoughtful. Answered all questions.
One star One star One star One star One star	06/27/2023	Very thorough explanation of my options answered all questions and concerns.
One star Empty star Empty star Empty star Empty star	06/18/2023	Care priovider is nurse, right!Care from Dr Steuer is great!
One star One star One star One star One star	06/15/2023	Good communication
One star Empty star Empty star Empty star Empty star	06/15/2023	They would not give me a video visit with oncologist Conor Steuer, even though I was having afib events and did not want to travel to the office. Delayed my treatment.
One star One star One star One star One star	06/11/2023	Listened to our concerns very understanding to the point
One star One star One star One star One star	06/09/2023	I am grateful and fortunate to have Doctor Steuer as my primary oncology doctor He is truly an expert in this field and has helped me through my lung cancer fight and given me back my quality of life. I place full trust in him when it comes to my treatment.
One star One star One star One star One star	04/21/2023	The very best!
One star One star One star One star One star	03/24/2023	All good
One star One star One star One star One star	03/10/2023	Dr Steuer and Lindsey Allen PA are amazing They truly care about me and my health
One star One star One star One star One star	03/09/2023	Dr. Steuer has always been a very Professional and caring Doctor. He communicates well with you and gives you the opportunity to speak as he listens with heartfelt interest. He is truly an Asset to Emory!